Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by yorgosGKon Apr 16, 2018 8:18pm

160 Views

Post# 27894575

RE:RE:RE:Someone wants this low, but only for the time being

Bingo...and for the record to clarify my lingo incase people are wondering. A short squeeze refers to a jump in a stock's price, forcing a large number of short sellers to close their position, which in effect pushes the price even higher. When an investor shorts a stock, he borrows shares from another account and sells them, agreeing to replace the stock at a later date. Remember the 2.5M shares that we knew nothing about....not saying this is it 100% but just connecting the dots.......do your own DD. Im not advising anything here - play it how you think :) I know I'm doubling up though...great opportunity. I TRUST THIS BOARD.....!

Bullboard Posts

Hyundai partners with BlackBerry for next-gen digital cockpit platform